Physician profile
Stefan Scheidler
NPI 1669525275
$4,703.73
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,382 · 2020: $1,216 · 2021: $1,266 · 2022: $660 · 2023: $134 · 2024: $46.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $180.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $788.57 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $474.87 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $471.29 | 2019-2023 | Jardiance, Tradjenta, Synjardy |
| Amarin Pharma, INC. | $363.69 | 2019-2021 | |
| Glaxosmithkline, LLC. | $352.03 | 2019-2022 | |
| Lilly USA, LLC | $323.64 | 2019-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $295.70 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $260.30 | 2019-2021 | |
| Pfizer INC. | $187.67 | 2019-2021 | |
| Astellas Pharma US INC | $185.27 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $136.38 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $117.75 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $106.30 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $94.67 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $85.92 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $73.67 | 2021-2024 | Uzedy |
| Amgen INC. | $60.61 | 2020-2022 | |
| Abbvie INC. | $43.00 | 2021-2022 | |
| Eisai INC. | $41.24 | 2020 | |
| Grifols USA, LLC | $32.22 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $26.58 | 2021 | |
| Ibsa Pharma INC. | $23.01 | 2020 | |
| Neurocrine Biosciences, INC. | $20.72 | 2023 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $18.56 | 2022 | |
| Nabriva Therapeutics, Plc | $17.15 | 2022 | |
| Shield Therapeutics INC | $16.41 | 2022 | |
| Nestle Healthcare Nutrition INC. | $15.98 | 2021 | |
| Corium, LLC | $15.63 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.17 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.94 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.52 | 2022 | |
| Abbott Laboratories | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefan Scheidler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.